Automata, a London-headquartered medtech company, has secured $40 million in funding to further develop its automated lab robots. The investment round was led by Dimension and included participation from A.P. Moller Holding, the parent company of the A.P. Moller Group, owners of laboratory testing group Unilabs. Existing investors such as Octopus Ventures, Hummingbird, Isomer Capital, Possible Ventures, and Aldea Ventures also joined in the funding round.
Expanding Reach and Impact
Automata plans to utilize the funds to accelerate its growth and expand its presence in key regions, including the US, UK, and EMEA. Additionally, the company aims to grow its team and enhance its brand recognition within the industry. The primary focus will be on seizing the fast-growing opportunities in the global life sciences sector.
Mostafa Elsayed, Founder and CEO of Automata, expressed his enthusiasm for the funding, stating, “Achieving a fundraise with exciting and experienced investors in a pretty challenging funding environment is a real endorsement of the potential and capabilities of our lab automation platform.” He emphasized that the funds would enable the company to continue developing products that transform how scientists work in their labs and accelerate the impact on people’s lives worldwide.
Nan Li, Co-Founder and Managing Partner of Dimension, highlighted the importance of automation in modern labs. He emphasized the need for lab automation systems that prioritize speed, reliability, reconfigurability, reproducibility, and scale. Automata’s LINQ system, with its modular software and hardware, aligns with these needs and promises to redefine the lab automation space.
A Strategic Partnership for Innovation
Chetan Mehta, Head of Growth Equity of A.P. Moller Holding, expressed delight in partnering with Automata. He acknowledged Automata as an emerging leader in modernizing and automating the global life science industry. Automata’s solutions facilitate increased throughput, reduced costs, and accelerated innovation in medical and life science research.
Transforming Lab Workflows
Founded in London in 2015 by Mostafa ElSayed and Suryansh Chandra, Automata is on a mission to enable rapid innovation, diagnosis, and discovery in life sciences. The company provides robotic automation solutions for labs in the life science sector, helping them scale up and achieve quicker results. Its product portfolio includes human collaborative and arm-based lab automation robots, designed for tasks such as drug screening, colony counting, and acid testing. Automata also offers cloud-enabled robot management software, allowing seamless scheduling and orchestration of lab protocols from a single platform.
Making Automation Accessible
Automata’s LINQ automation platform aims to democratize lab automation, catering to research institutions, hospital groups, pharmaceutical and biotech companies, and CROs. Whether labs are running high-throughput workflows or require dynamic protocol development, LINQ offers an easily adoptable automation solution.
Leading the Way in Lab Automation
Automata has already gained traction with a diverse customer base, including NHS Trusts, academic institutions, testing labs, CDMOs, CROs, and pharmaceutical and biotech companies. With its innovative automation solutions, Automata is poised to drive transformation in lab workflows and contribute to groundbreaking advancements in the life sciences sector.
London-based medtech company Automata has secured $40 million in funding to advance its lab automation robots. The investment will fuel the company’s growth and expand its presence across the US, UK, and EMEA. Automata’s automation solutions promise to revolutionize lab workflows in the life sciences sector, making them more efficient and accessible.
Hi, I’m Oren, founder at BIGINTRO, a content strategy agency that helps B2B companies drive growth. We develop search, social, PR, and content marketing strategies tailored to business goals. I also have a dog named Milo.